These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 29411547)
1. The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. Bridges SL; White DW; Worthing AB; Gravallese EM; O'Dell JR; Nola K; Kay J; Cohen SB; Arthritis Rheumatol; 2018 Mar; 70(3):334-344. PubMed ID: 29411547 [No Abstract] [Full Text] [Related]
2. 10 years of biosimilars: lessons and trends. Royzman I; Shah K Nat Rev Drug Discov; 2020 Jun; 19(6):375. PubMed ID: 32358591 [No Abstract] [Full Text] [Related]
3. Patent litigation could make 2017 no 'dancing' matter. Reinke T Manag Care; 2016 Dec; 25(12):23-28. PubMed ID: 28121555 [TBL] [Abstract][Full Text] [Related]
4. Biosimilars battle rages on, Amgen fights both sides. Senior M Nat Biotechnol; 2013 Apr; 31(4):269-70. PubMed ID: 23563402 [No Abstract] [Full Text] [Related]
5. The Biosimilar Pipeline Seams Seem To Be Bursting. Reinke T Manag Care; 2017 Mar; 26(3):24-25. PubMed ID: 28510516 [TBL] [Abstract][Full Text] [Related]
7. Biosimilars in the United States: Emerging Issues in Litigation. Wong AY; Rumore MM; Chan AW BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972 [TBL] [Abstract][Full Text] [Related]
9. The comparability conundrum: biosimilars in the United States, Europe and Canada. Courage N; Parsons A Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840 [TBL] [Abstract][Full Text] [Related]
10. Drug Development. Are trade secrets delaying biosimilars? Price WN; Rai AK Science; 2015 Apr; 348(6231):188-9. PubMed ID: 25859034 [No Abstract] [Full Text] [Related]
11. Biosimilar biologic drugs: a new frontier in medical care. Geynisman DM; De Velasco G; Sewell KL; Jacobs I Postgrad Med; 2017 May; 129(4):460-470. PubMed ID: 28343424 [TBL] [Abstract][Full Text] [Related]
13. Biosimilars: the need, the challenge, the future: the FDA perspective. Epstein MS; Ehrenpreis ED; Kulkarni PM; Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160 [TBL] [Abstract][Full Text] [Related]
14. Why Biosimilars Can Never Be Identical To Originators-and Why They Don't Need To Be. Reinke T Manag Care; 2019 Jan; 28(1):10-11. PubMed ID: 30883316 [TBL] [Abstract][Full Text] [Related]
16. Biosimilars Ready, At Last, To Make Their Entrance: Stars Are Born or Do They Fizzle? Reinke T Manag Care; 2017 Mar; 26(3):20-23. PubMed ID: 28510515 [TBL] [Abstract][Full Text] [Related]
17. Competition in the Age of Biosimilars. Chandra A; Vanderpuye-Orgle J JAMA; 2015 Jul; 314(3):225-6. PubMed ID: 26197179 [No Abstract] [Full Text] [Related]
18. Biologic Drugs, Biosimilars, and Barriers to Entry. Shepherd JM Health Matrix Clevel; 2015; 25():139-61. PubMed ID: 29485844 [TBL] [Abstract][Full Text] [Related]
19. Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet. Rychlick N Manag Care; 2018 Jan; 27(1):29. PubMed ID: 29369768 [TBL] [Abstract][Full Text] [Related]
20. Biosimilars: Rationale and current regulatory landscape. Olech E Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]